Patients should report any unexpected or severe symptoms through the Yellow Card Scheme (yellowcard.mhra.gov.uk), contributing to ongoing pharmacovigilance efforts that help identify rare adverse effects not apparent in pre-marketing trials
Retatrutide remains investigational, available only through research channels or clinical trials
Nicholas Louizos Person I mean, we can't default to a fee for service type system where the plans are responding to billed charges, which, you know, and I'm not saying this is the case in the behavioral health space, but it might be
Segment Analysis By Molecule: Tirzepatide Narrows Semaglutides Lead Semaglutide generated 42.56% of 2025 revenue, anchoring the glucagon-like peptide-1 agonists market through its dual diabetes-obesity branding and extensive outcomes data
In other words, they dont undergo the same rigorous clinical trials or quality checks before reaching patients
doi:10.1016/S0021-9258(18)61264-5